Advertisement

Jabbour Launches MSJ Healthcare Consulting

Advertisement

Michael Jabbour will call on his 25 years experience in advertising and pharmaceutical marketing in his new practice, MSJ Healthcare Consulting.

The Boston company offers stra-tegic and creative consulting services to marketing professionals in the healthcare sector.

"I don't have the Holy Grail, but I can challenge the way they look at their brand," said Jabbour.

With many advertising professionals turning to specialists as industry layoffs continue, is there room for another consultant? John Verret, a professor at Boston University's College of Communication, believes there is. "There's always room for consultants who specialize in something for which there is a market," particularly in a growing field such as healthcare, Verret said.

One of Jabbour's key clients is Eli Lilly in Indianapolis. He advises the company's global marketing directors on positioning drugs in development. Leading agency searches for the client is a possibility in coming months, when the treatments are closer to being marketed, he said.

He does not plan, however, to exclusively focus on conducting reviews.

Jabbour also works with Torre Lazur Mc-Cann Healthcare, a Parsippany, N.Y., agency owned by the Interpublic Group. His work there involves assisting the agency'sMulticultural Marketing Group in addressing health disparities among minorities and how to market products to African Americans, Asian Americans and Hispanics.

From 1997 to 1999 Jabbour was president of Lewis Gace Bozell Worldwide in Fort Lee, N.J., now part of IPG's Lowe Healthcare Group. During his nine-year tenure there, he held various positions and oversaw campaigns for clients such as Abbott Laboratories, Eli Lilly, Roche Laboratories, Daiichi Pharmaceuticals, Genentech and Glaxo Wellcome.

Before joining Lewis Gace, he worked for Chicago agencies Frank J. Corbett and the defunct Trunk Shea McCaffrey. His client-side career includes 12 years in various sales and product management positions at Beecham Laboratories, now GlaxoSmithKline.